Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Liminal BioSciences Inc. LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


Recent & Breaking News (NDAQ:LMNL)

Liminal BioSciences Announces Holding of Special Meeting of Shareholders

PR Newswire 12 days ago

Liminal BioSciences Reports Third Quarter 2022 Financial Results and Business Highlights

PR Newswire November 9, 2022

Liminal BioSciences to Report Third Quarter 2022 Financial Results on November 9, 2022

PR Newswire November 8, 2022

Liminal BioSciences Announces Listing Transfer to Nasdaq Capital Market

PR Newswire September 1, 2022

Liminal Biosciences to Present at H.C. Wainwright 24th Annual Global Investment Conference

PR Newswire August 29, 2022

Liminal BioSciences Announces Termination of Legacy CDMO Contract

PR Newswire August 25, 2022

Liminal BioSciences Reports Second Quarter 2022 Financial Results and Business Highlights

PR Newswire August 9, 2022

Liminal BioSciences Announces Discontinuation of Fezagepras Development

PR Newswire July 21, 2022

Liminal BioSciences Announces Voting Results of its 2022 Annual General Meeting of Shareholders

PR Newswire June 6, 2022

Liminal BioSciences Announces First Subject Dosed in Phase 1a Single Ascending Dose Clinical Trial of Fezagepras

PR Newswire May 23, 2022

Liminal BioSciences Reports First Quarter 2022 Financial Results and Business Highlights

PR Newswire May 10, 2022

Liminal BioSciences to Report First Quarter 2022 Financial Results on May 10, 2022

PR Newswire May 9, 2022

Liminal Biosciences to Present at Upcoming Investor Conferences

PR Newswire May 9, 2022

Liminal BioSciences Reports Fourth Quarter and Year End 2021 Financial Results

Canada NewsWire March 17, 2022

Liminal BioSciences Provides Update on Its Lead Drug Candidate Fezagepras

PR Newswire March 14, 2022

Liminal BioSciences Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement

PR Newswire March 7, 2022

Liminal BioSciences Repays its Secured Debt Ending its Creditor Relationship with Structured Alpha LP

PR Newswire February 16, 2022

Liminal BioSciences Announces Strategic Priorities For 2022

PR Newswire January 19, 2022

Liminal BioSciences Reports Third Quarter 2021 Financial Results

PR Newswire November 15, 2021

Liminal BioSciences Announces Closing of Sale of Remaining Plasma-Derived Therapeutics Business

PR Newswire October 15, 2021